3 results
Primary objective: To establish the MSSD of INC424 in patients with MF and baseline PLT count < 100 x 109/L and * 75 x 109/L (first stratum) and PLT count < 75 x 109/L and * 50 x 109/L (second stratum).Secondary objective: safety, PK,…
Primary objectivesTo evaluate the effect of the CYP1A2 inhibitor, fluvoxamine, on steady state pharmacokinetics of TKI258 in patients with advanced solid tumors, excluding breast cancerSecondary objectives• To characterize the safety and…
In this study we will look at how quickly and to what extent the study compound MEN1611 is absorbed, transported, and eliminated from the body (this is called pharmacokinetics) and how this is influenced by the approved drug itraconazole fluvoxamine…